Orphazyme is in dialog with a number of potential suitors in search of rescue

Biotech company Orphazyme is in need of a lifeline, and its deputy chair, Bo Jesper Hansen, is in talks with five to ten potential buyers and investors as a part of current restructuring plans.

Bo Jesper Hansen, deputy chair of the board at Orphazyme | Photo: Kåre Viemose

On Thursday, Orphazyme released its restructuring plan, stating that potential investors and buyers had already been identified and contacted.

According to Orphazyme’s deputy chair of the board of directors, Bo Jesper Hansen, the number of suitors can be counted on two hands, and the list is mostly comprised of other pharmaceutical and biotech companies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs